التفاصيل البيبلوغرافية
| العنوان: |
Management of hepatocellular carcinoma with novel immunotherapeutic agents and prospects for the future. |
| المؤلفون: |
Szklener, Katarzyna1 katarzyna.szklener@op.pl, Piwoński, Michał2, Żak, Klaudia2, Szarpak, Julita2, Niedobylski, Sylwiusz2, Stanicki, Paweł3, Szklener, Sebastian4, Mańdziuk, Sławomir1 |
| المصدر: |
Nowotwory. 2021, Vol. 71 Issue 6, p391-400. 10p. |
| مصطلحات موضوعية: |
*LIVER cancer, *HEPATOCELLULAR carcinoma, *MORTALITY, *SORAFENIB, *TYROSINE |
| مستخلص: |
The most frequent type of primary liver cancer is hepatocellular carcinoma (HCC). Although HCC is not the most frequent cancer, it is characterized by high mortality - the 5-year survival rate is 6,9%. In recent decades there was only one molecule available in treatment (sorafenib). However, in the past few years there have been advances in treatment. Nowadays, new generation tyrosine kinase inhibitors, check point inhibitors and anti-angiogenesis drugs are available. All those studies were analyzed outcome in context of monotherapy or combined therapies. In this review we made an attempt to compare results from different studies. Even though, many studies are undergoing final stages of clinical trials, it seems that combined therapies should be the next step in treatment advances. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
